Clinical AdvancementsTrem-cel continues to demonstrate high engraftment rate, shielding from MYLOTARG on-target toxicity with a broader therapeutic window, and early evidence of improved relapse free survival.
Regulatory ProgressFDA does not require additional data to start the Phase III trial and agreed with VOR on its design.
Scientific And Clinical ThesisThe transformative potential of trem-cel and VCAR33 in treating AML/MDS is supported by clinical data, enhancing the company's scientific and clinical thesis.